Enzon Extends Preferred Stock Exchange Offer Amid Merger

An announcement from Enzon Pharmaceuticals ( (ENZN) ) is now available.

On March 19, 2026, Enzon Pharmaceuticals announced it had extended the expiration of its exchange offer for holders of its Series C Non-Convertible Redeemable Preferred Stock, allowing investors additional time until 5:00 p.m. Eastern on March 24, 2026, to swap those shares for Enzon common stock, unless the offer is further extended. The move comes as Enzon advances its planned merger with Viskase Companies, Inc., supported by an SEC-filed registration statement for the combined entity, underscoring the company’s ongoing restructuring of its capital structure and corporate profile ahead of the proposed transaction.

The exchange offer extension may influence the ultimate mix of preferred and common equity in the merged company and could affect relative ownership levels among current Enzon stakeholders, who are being asked to evaluate the exchange alongside the broader merger terms. The transaction remains subject to various closing conditions and regulatory and shareholder approvals, and both Enzon and Viskase highlight a wide range of risks that could delay or derail completion, including potential litigation, business disruptions and adverse reactions from key stakeholders during the pendency of the deal.

More about Enzon Pharmaceuticals

Enzon Pharmaceuticals operates in the life sciences sector and is publicly traded, with both preferred and common stock outstanding. The company is currently engaged in a proposed merger transaction with packaging specialist Viskase Companies, Inc., and has filed a registration statement with the U.S. Securities and Exchange Commission that details financial information for the combined company.

Average Trading Volume: 76,726

Technical Sentiment Signal: Sell

Current Market Cap: $4.45M

See more data about ENZN stock on TipRanks’ Stock Analysis page.